Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1
Glucose and Insulin Response Over 6 days:
Clinical Data Posted at World ADA Diabetes & Obesity Conference
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology.
